The scientific community’s fascination with macrocyclic structures has evolved significantly over the last several decades. When we talk about all cyclic peptides ever identified, we are looking at a vast, structural frontier defined by polype 29 Oct 2020—“Papers stated with more and more certainty over the years thatcyclolinopeptide A (from flax) was the first such peptide discovered,” he said.Read more ptide chains which contain a circular sequence of bonds. These molecules, ranging from small natural isolates to complex synthetic constructs, represent a dynamic and promising class of bioactive compounds that continue to intri by ML Merz·2024·Cited by 125—The 10cyclic peptidesvaried strongly in their stability, with half-lives ranging from 11 min (peptide 1) to 133 min (peptide 2) (Fig. 1b), Read more gue researchers worldwide.
Understanding the Structural Architecture
At their core, cyclic peptides are defined by their unique topology. Unlike linear counterparts, these are polypeptide chains that are formed by a cyclic sequence of 5 to 14 amino acids, typically exhibiting a molecular weight between 500 and 2000 Da. This "closed-loop" architecture provides immense structural rigidity, which is a primary reason why cyclic peptides are among the most diverse architectures for current drug discovery efforts.
From a historical perspective, the discovery of cyclolinopeptide A (from flax) marked a significant milestone in recognizing these structures in nature. Today, we know that they are widely found in nature, isolated from microorganisms, plants, and animals. Early pioneers in this field include the study of oxytocin and vasopressin, which were among the first hormones to highlight the efficacy of cyclic scaffolds.
The Evolution of Clinical Utility
The progression of these molecules from the lab to application is well-documented. Currently, there are over 40 cyclic peptides in clinical use, demonstrating their stability and biological relevance. A notable body of research highlights 18 cyclic peptides approved for clinical use in the past two decades, underscoring a steady ris by H Zhang·2021·Cited by 339—In this review, we will discuss and summarize18 cyclic peptides approved for clinical use in the past two decadesto provide a better understanding of cyclic Read more e in their adoption.
Among the notable examples are:
* Cagrilintide: A mod Discover a list ofFDA-approved cyclic peptide drugs, their therapeutic uses, and significance in modern medicine. ern example of an engineered peptide sequence.
* Calcitonin, oxytocin, somatostatin, and vasopressin: The classic hormones that paved the way for the field.
* FDA-approved cyclic peptide drugs: These include specialized agents for various conditions, frequently utilized as molecules that are already used as drugs in therapies.
Data-Driven Insights and Databases
For those tracking the sheer volume of these compounds, the CycPeptMPDB provides a comprehensive look at the field. This database catalogs 7,991 structurally diverse cyclic peptides, offering researchers a centralized knowledge base to study their stability, permeability, and potential for interaction with biological targets. Whether it is custom synthesis of cyclic peptides—involving lactam, disulfide-bridged, or stapled scaffolds—or the exploration of novel "one-pot" synthesis methods, the ability to manipulate these structures has never been greater.
Personal Perspectives on Peptid In this review, we will discuss and summarize18 cyclic peptides approved for clinical use in the past two decadesto provide a better understanding of cyclic Read more e Research
In my experience exploring the biochemical tools available today, the shift toward these macrocycles by ML Merz·2024·Cited by 125—The 10cyclic peptidesvaried strongly in their stability, with half-lives ranging from 11 min (peptide 1) to 133 min (peptide 2) (Fig. 1b), Read more is clear. The rigidity of the cyclic bond prevents the rapid degradation often seen in linear peptides, making them highly attractive for those studying protein-protein interactions. While the list of all cyclic peptides continues to grow through high-throughput screening and de novo design, the core appeal remains the same: the perfect balance of size, stability, and specific binding affinity.
As we look toward the future, the integration of computational design and synthetic biology will likely expand the catalog of these molecules even further. Whether you are reviewing the history of 18 cyclic peptides approved for clinical use in the pas Evolution of approved peptide drugs over the years. t two decades or analyzing the latest entries in a specialized database, it is evident that these structures are here to stay, continuing to redefine the boundaries of what is possible in molecular science.